Clinical trials: SARS
Severe Acute Respiratory Syndrome
The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes
Severe acute respiratory syndrome (SARS) is a new threat to public health since November, 2002. The SARS is highly contagious and is believed to be transmitted by person-to-person through droplet and direct contact.
- Trial name
- NCT00172263
- Testing
- blood sampling
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
SARS-CoV Infection, Respiratory Viral Infection
COVID-19 Testing Sample Acquisition Throughput and Efficiency
This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and…
- Conditions
- SARS-CoV Infection, Respiratory Viral Infection, Personal Protective Equipment, Covid19
- Trial name
- HexapodBooth (NCT04532411)
- Testing
- Personal Protective Testing Booth
- Where
- United States
- Volunteers
- 28,948 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
Coronavirus-induced disease 2019 (COVID-19) is an infection caused by a virus whose full name is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- INHERIT (NCT05204550)
- Testing
- unfractionated heparin, 0.9%sodium chloride
- Where
- Australia
- Volunteers
- 506 people
- Sponsor
- Murdoch Childrens Research Institute
Emergencies, Epidemic Disease
Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns
A retrospective cohort study to explore the impact of the FIFA World Cup 2022 Qatar on paediatric emergency department attendance at two tertiary centres during unprecedent winter viral epidemics.
- Conditions
- Emergencies, Epidemic Disease, Pediatric ALL, Electronic Medical Record
- Trial name
- NCT05818215
- Testing
- NO intervention
- Where
- Switzerland
- Volunteers
- 18,000 people
- Sponsor
- Pediatric Clinical Research Platform
Cystic Fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT05074680)
- Testing
- Blood sampling
- Where
- 2 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19 Pandemic
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine
This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the safety and immunogenicity of SCTV01E in population of different ages who have been vaccinated against COVID-19.
- Trial name
- SCTV01E (NCT05652543)
- Testing
- SCTV01E
- Where
- 4 sites in China
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Sars-CoV2, Breastmilk
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b
The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants.
- Trial name
- NCT04453982
- Testing
- Human milk donors
- Where
- Canada
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Deborah O'Connor
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration…
- Trial name
- NCT05135455
- Where
- 6 sites in Japan
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Covid19
PCR Cycle Threshold Values and COVID-19 Outcomes
This is a retrospective observational study. The study will use high quality, reliable data that has already been collected for the ISARIC 4C COVID-19 study in order to analyse the relation between predictor variables (laboratory…
- Trial name
- NCT04651413
- Testing
- PCR Value
- Where
- United Kingdom
- Volunteers
- 934 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
The study is to provide reliable estimates of the effect of study treatment on hospital length of stay through to 28 days after randomisation.
- Trial name
- NCT04826588
- Testing
- Methylprednisolone sodium succinate 10 mg/kg intravenously, Human normal immunoglobulin (IVIg)
- Where
- 10 sites in Switzerland
- Volunteers
- 76 people
- Sponsor
- University Children's Hospital Basel
Severe Acute Respiratory Syndrome Coronavirus 2
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.
- Trial name
- NCT04360486
- Testing
- Anti-Sars-CoV-2 Convalescent Plasma
- Where
- 38 sites in United States, Afghanistan and 6 more
- Sponsor
- U.S. Army Medical Research and Development Command
SARS-CoV2 Infection, Multisystem Inflammatory Syndrome in Children
MISC COVID-19 Study in Pediatric Population
Rationale: Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV2) and its related Coronavirus Disease - 19 (COVID-19) has become a health emergency worldwide.
- Trial name
- COVID-19 (NCT04844242)
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Tuberculosis Research Centre, India
SARS-CoV-2 Infection, Influenza A
Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test
This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and differentiation of SARS-CoV-2, Influenza A, Influenza B and RSV in AN…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
- Trial name
- CorDx 4in1 (NCT07875270)
- Testing
- Flu A/B/COVID-19 + RSV Multiplex Rapid Test
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorDx, Inc.
COVID-19; and High Infection Risk of SARS-CoV-2
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016 (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese…
- Trial name
- NCT04441918
- Testing
- JS016 (anti-SARS-CoV-2 monoclonal antibody)
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection Viral
RNA Sequencing of Individual Versus Wastewater - SARS-CoV2
The aim is to compare the percentage of the different SARS-CoV2 lineages that are detected in wastewater samples with matched clinical samples.
- Trial name
- Cagablea (NCT05041764)
- Testing
- NO INTERVENTION
- Where
- 2 sites in France
- Volunteers
- 1,409 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems